🇪🇺 Ryzodeg® in European Union

EMA authorised Ryzodeg® on 21 January 2013

Marketing authorisation

EMA — authorised 21 January 2013

  • Application: EMEA/H/C/002499
  • Marketing authorisation holder: Novo Nordisk A/S
  • Local brand name: Ryzodeg
  • Indication: Treatment of diabetes mellitus in adults, adolescents and children from the age of 2 years.
  • Status: approved

Read official source →

Ryzodeg® in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Ryzodeg® approved in European Union?

Yes. EMA authorised it on 21 January 2013.

Who is the marketing authorisation holder for Ryzodeg® in European Union?

Novo Nordisk A/S holds the EU marketing authorisation.